Real-world data on therapy response to inflammatory bowel disease biological treatments in patients with concurrent primary sclerosing cholangitis: a case-control study

Key Points

• Nonresponse to biological treatments is prevalent in inflammatory bowel disease patients, particularly those with PSC.
• The study evaluates responses in patients with ulcerative colitis and crohn's disease and emphasizes PSC's impact.
• Case-control study design provides insights into therapy effectiveness among IBD patients experiencing complications.
• Findings may inform treatment strategies for IBD patients, suggesting the need for tailored approaches in concurrent PSC cases.